Adams Respiratory Therapeutics ARXT
-
Adams under Review
We are placing Adams Respiratory Therapeutics ARXT under review until we can publish a new report that reflects Reckitt Benckiser's tender offer.
-
Reckitt to Acquire Adams
Adams Respiratory Therapeutics ARXT announced Monday that it would be acquired by U.K. consumer and health-care product company Reckitt Benckiser for $60 per …
-
Adams Boosts Revenue Outlook
Adams Respiratory ARXT announced October 29 that it expects 2008 revenue to be at the higher end of its guidance range due to higher-than-expected …
-
Adams Reports 4Q and Generic Threat
Adams Respiratory Therapeutics ARXT announced fourth-quarter results on Tuesday as well as notice from Perrigo PRGO that the generic drug company has submitted an …
-
Adams Gets More Mucinex Exclusivity
Adams Respiratory ARXT announced Friday that the Food and Drug Administration will mandate that, within 90 days, Adams' competitors stop selling timed …
-
Adams Settles Patent Lawsuit
On Thursday, Adams Respiratory Therapeutics ARXT announced a favorable settlement with Mutual Pharmaceutical regarding the long-acting guaifenesin patent-infringement lawsuit …
-
Adams Expects Lower Product Orders
Adams Respiratory ARXT announced on March 16 that it expects lower sequential sales for the remaining two quarters in its fiscal year. It also stated …
-
Adams' 2Q In Line; CFO Resigns
Adams Respiratory Therapeutics ARXT reported fiscal second-quarter results Wednesday that were in line with our expectations, and we are maintaining our fair value …
-
Adams' Year Off to Good Start
Adams Respiratory Therapeutics ARXT reported first-quarter earnings Wednesday that were in line with our expectations, so we're keeping our fair value estimate …
-
Adams Respiratory 4Q in Line
Adams Respiratory ARXT reported positive fourth-quarter and full fiscal-year earnings that were in line with our expectations. We're keeping our …